The Science Of Oral Carbapenems,
2023
Roseman University of Health Sciences
The Science Of Oral Carbapenems, Landon Olsen, Daniel J. Yang, Aiyi Chen, Thahn-Liem Vu, H. Stephen Lee
Annual Research Symposium
No abstract provided.
The Immunomodulating Effects Of Morphine Dependence And Withdrawal In Rat Lung, Liver, Spleen And Blood,
2023
Roseman University of Health Sciences
The Immunomodulating Effects Of Morphine Dependence And Withdrawal In Rat Lung, Liver, Spleen And Blood, Yensi Munoz
Annual Research Symposium
No abstract provided.
The Current State Of Underrepresented Osteopathic Minorities In Competitive Specialties,
2023
Noorda College of Osteopathic Medicine
The Current State Of Underrepresented Osteopathic Minorities In Competitive Specialties, Emmanuel Oyalabu, Steve Guzman, Dashon Eure, Ezenna Obilor
Annual Research Symposium
It is well documented that barriers exist for underrepresented minorities to enter the field of medicine and even more competitive residencies. As defined by the NRMP, competitive specialties include but are not limited to Interventional Radiology, Orthopedic Surgery, Plastic Surgery, Radiation Oncology, Vascular Surgery, Neurosurgery, Dermatology, and Otornylogy (NRMP-AMA). A large number of osteopathic medical school graduates have a history of going into primary care specialties because many osteopathic medical schools have a primary care focus (Primary Care- Osteopathic Medicine). The emphasis on primary care, whether intentional or not, can foster a less-than-advantageous environment for underrepresented minority students (URM), pursuing …
Appearance Of Two Distinct Clusters Of Glucose Dysregulation In Chronic Intractable Migraine,
2023
Noorda College of Osteopathic Medicine
Appearance Of Two Distinct Clusters Of Glucose Dysregulation In Chronic Intractable Migraine, Roshni Jogin, Kaitlyn Mcfarland, Aparna Naik, Tanner Williford, Matthew Conway, Amar Paul, John A. Kriak, David W. Sant, Kyle B. Bills
Annual Research Symposium
No abstract provided.
Heterodyned Whole-Body Vibration Ameliorates Anxiety In Opioid-Use Disorder,
2023
Noorda College of Osteopathic Medicine
Heterodyned Whole-Body Vibration Ameliorates Anxiety In Opioid-Use Disorder, Kailee Edwards, Braden Cunningham, Alfred Amendolara, Marryam Anwar, Jon Gonzales, Roshni Jogin, Wyatt Magoffin, Amar Paul, Ryan Perry, James Pike, Nathan Swallow, Steven Tung, Mary Seamons, Andrew Payne, John A. Kriak, David W. Sant, David W. Sant
Annual Research Symposium
No abstract provided.
Planning A Review Of The Pathogenesis And Management Of Valley Fever,
2023
Roseman University of Health Sciences
Planning A Review Of The Pathogenesis And Management Of Valley Fever, Seattle Shakur
Annual Research Symposium
No abstract provided.
Clinical Trial Subject Recruitment: Research Immersion Experience,
2023
Roseman University of Health Sciences
Clinical Trial Subject Recruitment: Research Immersion Experience, Brooklyn Janes
Annual Research Symposium
No abstract provided.
Serdexmethylphenidate/Dexmethylphenidate – A Promising Treatment Option For Childhood Attention Deficit Hyperactivity Disorder (Adhd),
2023
Roseman University of Health Sciences
Serdexmethylphenidate/Dexmethylphenidate – A Promising Treatment Option For Childhood Attention Deficit Hyperactivity Disorder (Adhd), N Troy To, H Stephen Lee
Annual Research Symposium
To review the phase 2 and phase 3 clinical trials of Serdexmethylphenidate and dexmethylphenidate (SDX/d-MPH) in the treatment of Attention Deficit/Hyperactivity disorder (ADHD) in children.
Mclena-1: A Phase Ii Clinical Trial For The Assessment Of Safety, Tolerability, And Efficacy Of Lenalidomide In Patients With Mild Cognitive Impairment Due To Alzheimer's Disease; Trial Design And Rationale,
2023
Roseman University of Health Sciences
Mclena-1: A Phase Ii Clinical Trial For The Assessment Of Safety, Tolerability, And Efficacy Of Lenalidomide In Patients With Mild Cognitive Impairment Due To Alzheimer's Disease; Trial Design And Rationale, Boris Decourt
Annual Research Symposium
No abstract provided.
Sulopenem For The Treatment Of Complicated And Uncomplicated Bacterial Urinary Tract Infection (Uti),
2023
Roseman University of Health Sciences
Sulopenem For The Treatment Of Complicated And Uncomplicated Bacterial Urinary Tract Infection (Uti), Aiyi Chen, Thanh-Liem Vu, Daniel J. Yang, Landon Olsen
Annual Research Symposium
No abstract provided.
Eflapegrastim-Xnst: A New Agent To Prevent Antineoplastic Chemotherapy-Induced Febrile Neutropenia,
2023
Roseman University of Health Sciences
Eflapegrastim-Xnst: A New Agent To Prevent Antineoplastic Chemotherapy-Induced Febrile Neutropenia, Gary Lynch
Annual Research Symposium
No abstract provided.
Oral Sulopenem And Tebipenem For Complicated Urinary Tract Infection And Pyelonephritis In Patients With Extended-Spectrum Beta-Lactamase (Esbl)-Producing Gram Negative, Susceptible Bacteria,
2023
Roseman University of Health Sciences
Oral Sulopenem And Tebipenem For Complicated Urinary Tract Infection And Pyelonephritis In Patients With Extended-Spectrum Beta-Lactamase (Esbl)-Producing Gram Negative, Susceptible Bacteria, Daniel J. Yang, Thanh-Liem Vu, Landon Olsen, Aiyi Chen, H Stephen Lee
Annual Research Symposium
ESBL-producing gram negative Enterobacteria is becoming more prevalent, and carbapenems play a key role in combating against ESBL for complicated urinary tract infections (cUTI). However, carbapenems are only available intravenously in the U.S. FDA is currently reviewing the newly developed oral carbapenems (sulopenem and tebipenem) and have requested additional clinical trial information before granting approval for cUTI. Currently available phase 3 clinical trials for tebipenem and sulopenem are reviewed.
Focus Group Interview Experience Of A University Clinical Research Team,
2023
Roseman University of Health Sciences
Focus Group Interview Experience Of A University Clinical Research Team, Kade Janes
Annual Research Symposium
No abstract provided.
Development Of A Census Driven Equation To Predict Non-Billable "Cross-Cover" Work Done During Nocturnist Shifts To Predict Staffing,
2023
Roseman University of Health Sciences
Development Of A Census Driven Equation To Predict Non-Billable "Cross-Cover" Work Done During Nocturnist Shifts To Predict Staffing, Bibhash Neupane
Annual Research Symposium
No abstract provided.
Roseman Research Symposium,
2023
Roseman University of Health Sciences
Roseman Research Symposium, Manas Mandal
Annual Research Symposium
No abstract provided.
Vital Pulp Therapy: “What’S New When Visiting An Old Friend”?,
2023
Roseman University of Health Sciences
Vital Pulp Therapy: “What’S New When Visiting An Old Friend”?, John Francis Wisniewski
Annual Research Symposium
Roseman Health Sciences Research Symposium
Emergence Of Dental Nanomaterials: “Their Role In Performing Endodontic Therapy”,
2023
Roseman University of Health Sciences
Emergence Of Dental Nanomaterials: “Their Role In Performing Endodontic Therapy”, Chandrika Nama, John Wisniewski Dr.
Annual Research Symposium
No abstract provided.
The Impact Of A Hospital Protocol In Neonates At Risk For Neonatal Abstinence Syndrome (Nas),
2023
Roseman University of Health Sciences
The Impact Of A Hospital Protocol In Neonates At Risk For Neonatal Abstinence Syndrome (Nas), Victoria Pang
Annual Research Symposium
No abstract provided.
New Year, New Variant Or A Subvariant Of Old Omicron?,
2023
Roseman University of Health Sciences
New Year, New Variant Or A Subvariant Of Old Omicron?, Parker Grossman, Manas Mandal
Annual Research Symposium
No abstract provided.
Adverse Infusion-Related Event Severity In Oncology Patients Receiving Chemotherapy Agents Vs. Immunotherapy Agents,
2023
Roseman University of Health Sciences
Adverse Infusion-Related Event Severity In Oncology Patients Receiving Chemotherapy Agents Vs. Immunotherapy Agents, Tayler Hutto
Annual Research Symposium
In recent years, immunotherapy investigational drugs in cancer research has been underway in treating multiple forms of cancer due to a lower side effect profile and decreased severe infusion-reaction risk compared to conventional chemotherapy agents. The purpose of this study was to determine the infusion reaction severity among patients receiving either chemotherapy treatment or immunotherapy agents based on the CTCAE (Common Terminology Criteria for Adverse Events) scale to improve patient care outcomes.
In this intent-to-treat, retrospective observational study, a survey of patients throughout 10 Intermountain Healthcare infusion clinics was conducted to obtain documentation on patients who had received chemotherapy and/or …
